Jiangsu Aidi Pharmaceutical Co., Ltd. Indicative announcement on the reduction of shareholders holding more than 5% of the shares to 1%.

Stock code: 688488 Stock abbreviation: Eddy Pharmaceutical Announcement number: 2021-048

The Board of Directors and all Directors of the Company warrant that the contents of this announcement are free from any misrepresentation, misleading statements or material omissions, and assume legal responsibility for the truthfulness, accuracy and completeness of the contents in accordance with the law.

Important Content Tips:

● This change of interest is to fulfill the previously disclosed share reduction plan and does not touch the tender offer;

● The change in equity is a reduction of the non-largest shareholder holding more than 5% of the total shares, which will not change the controlling shareholder and actual controller of the company;

● After the change of rights, the number of shares held by the information disclosure obligor was 26,136,793 shares, and the proportion of shares held by the company was reduced from 7.22% to 6.22%.

On October 26, 2021, Jiangsu Aidi Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") received the "Notification Letter on the Progress of the Share Reduction Plan" from the shareholder of the Company, Jiangsu Yida M&A Growth Equity Investment Fund (Limited Partnership) (hereinafter referred to as "M&A Growth") and its co-actors Jiangsu Gaotou Xinhai Venture Capital Co., Ltd. (hereinafter referred to as "Gaotou Xinhai") and Jiangsu Talent Innovation and Venture Capital Partnership (Limited Partnership) (hereinafter referred to as the "Talent Fund"). The relevant changes in its interests are hereby announced as follows:

1. The change of rights and interests

remark:

1. The shares involved in this change of rights and interests all enjoy voting rights, and there is no restriction or restriction on the transfer of any rights such as the delegation or restriction of voting rights;

2. There is no violation of the Securities Law, the Measures for the Administration of Takeovers of Listed Companies and other laws and regulations, as well as the relevant provisions of the Shanghai Stock Exchange business rules and their relevant commitments;

3. The discrepancy between the total number and the sum of the sub-values in the above table is due to rounding.

2. Before and after the change of rights and interests, the information disclosure obligor has shares of the company's interests

1. The shares of the company held after the change of rights and interests shall enjoy voting rights, and there is no restriction or restriction on the transfer of any rights such as the delegation or restriction of voting rights;

2. The discrepancy between the total number and the sum of the sub-values in the above table is due to rounding.

3. Other information descriptions

1. The change of equity is a reduction in shareholding, does not touch the tender offer, and does not involve the source of funds;

2. The change of rights and interests is the implementation of the share reduction plan, the specific content of which is detailed in the "Announcement of the Centralized Bidding And Reduction Plan for Shareholders of Jiangsu Aidi Pharmaceutical Co., Ltd." (Announcement No. 2021-034) disclosed by the Company on the Shanghai Stock Exchange (www.sse.com.cn) on July 21, 2021, and the reduction plan has not been implemented so far;

3. The change of equity is the reduction of non-first shareholder holding more than 5% of the total shares, which will not lead to a change in the controlling shareholder and actual controller of the company;

4. The change in shareholders' equity does not involve the information disclosure obligor's disclosure of the change in equity report.

This is hereby announced.

Jiangsu Aidi Pharmaceutical Co., Ltd

board of directors

October 27, 2021